Abstract:Since the FDA’s approval of chimeric antigen receptor (CAR) T cells in 2017, significant improvements have been made in the design of chimeric antigen receptor constructs and in the manufacturing of CAR T cell therapies resulting in increased in vivo CAR T cell persistence and improved clinical outcome in certain hematological malignancies. Despite the remarkable clinical response seen in some patients, challenges remain in achieving durable long-term tumor-free survival, reducing therapy associated malignancies and toxicities, and expanding on the types of cancers that can be treated with this therapeutic modality. Careful analysis of the biological factors demarcating efficacious from suboptimal CAR T cell responses will be of paramount importance to address these shortcomings. With the ever-expanding toolbox of experimental approaches, single-cell technologies, and computational resources, there is renowned interest in discovering new ways to streamline the development and validation of new CAR T cell products. Better and more accurate prognostic and predictive models can be developed to help guide and inform clinical decision making by incorporating these approaches into translational and clinical workflows. In this review, we provide a brief overview of recent advancements in CAR T cell manufacturing and describe the strategies used to selectively expand specific phenotypic subsets. Additionally, we review experimental approaches to assess CAR T cell functionality and summarize current in silico methods which have the potential to improve CAR T cell manufacturing and predict clinical outcomes.

Tuning the performance of CAR T cell immunotherapies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Tuning CAR T-cell therapies for efficacy and reduced toxicity

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Driving CAR T-cells forward

CAR T cells: Building on the CD19 paradigm

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

From bench to bedside: the history and progress of CAR T cell therapy

CAR T‐cell therapy: Full speed ahead

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Engineering Enhanced CAR T-cells for Improved Cancer Therapy.

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

CAR T Cells: A Snapshot on the Growing Options to Design a CAR

Development of CAR T cells designed to improve antitumor efficacy and safety